These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 17414515)

  • 1. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
    Simons JW; Sacks N
    Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine therapy for prostate cancer.
    Sonpavde G; Spencer DM; Slawin KM
    Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF
    Cancer J; 2008; 14(1):26-34. PubMed ID: 18303480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-based therapies for prostate cancer.
    McNeel DG; Malkovsky M
    Immunol Lett; 2005 Jan; 96(1):3-9. PubMed ID: 15585302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
    Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
    Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of high risk metastatic prostate cancer: the case for novel therapies.
    Brand TC; Tolcher AW
    J Urol; 2006 Dec; 176(6 Pt 2):S76-80; discussion S81-2. PubMed ID: 17084174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic targeting: how to channel a minimal response for maximal outcome.
    Slovin SF
    Curr Opin Urol; 2006 May; 16(3):179-85. PubMed ID: 16679856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer vaccines: current status.
    Hwang LC; Fein S; Levitsky H; Nelson WG
    Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immunotherapies for prostate cancer.
    McNeel DG
    Biomed Pharmacother; 2007 Jul; 61(6):315-22. PubMed ID: 17306498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vaccines for prostate cancer.
    Cha E; Fong L
    Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
    Slovin SF
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.